Other languages GeoVax Labs, Inc.

Equities

GOVX

US3736786068

Market Closed - Nasdaq Other stock markets 02:00:00 04/05/2024 am IST			5-day change	1st Jan Change
1.61 ^USD	+13.38%		+13.38%	-70.27%

28/03	GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress	CI
06/03	GeoVax Labs, Inc. Achieves Milestone in Transition to Commercially Validated Manufacturing System	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress	28/03
GeoVax Labs, Inc. Achieves Milestone in Transition to Commercially Validated Manufacturing System	06/03
GeoVax Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/03
GeoVax Labs Gets Two Patents from US Patent and Trademark Office	13/02
Geovax Reports Positive Interim Data from Phase 2 Clinical Trial of Geo-Cm04s1 as A Universal Covid-19 Vaccine Booster	06/02
Geovax Appoints Marc Pipas as Executive Medical Director, Oncology	08/01
GeoVax Labs, Inc. Announces Gedeptin Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients	04/01
GeoVax Labs Files for 21.1 Million Share Offering by Selling Shareholder	03/01
Geovax Labs, Inc. Announces the Presentation of Preclinical Vaccine Efficacy Data for GEO-CM02	14/11
GeoVax Labs, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
GeoVax Labs, Inc. Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine	30/23/30
GeoVax Labs Gets Notice of Allowance for US Patent Application Covering Marburg Vaccine	09/23/09
GeoVax Labs' HIV Vaccine Patent Gets Notice of Allowance from US Patent and Trademark Office	05/23/05
GeoVax Labs, Inc. Secures Multi-Product License for Probiogen's Age1.Cr.Pix(R) Suspension Cell Line to Bolster MVA-Based Vaccine Development	26/23/26
Geovax Labs, Inc. Next-Generation Covid-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients	19/23/19
GeoVax Labs, Inc. Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster	11/23/11
GeoVax Labs Says it Received Allowance Notice for Malaria Vaccine Patent Application	28/23/28
GeoVax Labs, Inc. Announces First Patients Vaccinated in Phase 2 Clinical Trial of Covid-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia	10/23/10
GeoVax Labs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10
GeoVax Labs, Inc. Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia	20/23/20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages GeoVax Labs, Inc.

Equities

GOVX

US3736786068

Other languages

Filters